SkyePharma and Nippon-Shinyaku Announce Distribution Agreement For DepoCyt(TM) in Japan
(PR Newswire)... need for surgical insertion of a reservoir into the brain that is often necessary for frequent administration......Prevalence is dependent on tumor type and is estimated at up to 25% of patients with...... estimated at up to 25% of patients with late-stage solid tumors and up to 20% of patients with certain types of lymphoma....- Jul 02 7:30 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010702/nym009.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines